NHS Lanarkshire R&D
Airdrie, ML6 0JS, United Kingdom
NCT Number: NCT02196246
To evaluate an iPad based photoimage analysis system (Moletest) for improving discrimination of benign from malignant suspicious skin lesions or moles. Specifically the objective is to demonstrate that the Moletest system is able with a sufficient degree of confidence (95%) to identify lesions which are benign
Looking for future studies?
Notify MeAll sexes
Observational
Airdrie, ML6 0JS, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
All patients referred to the Dermatology Department, Lanarkshire Hospitals during a period to be defined for assessment of suspicious skin lesions (cutaneous moles) will be eligible for inclusion in the study. There are no age limits but patients under the age of 18 years will also have their inclusion subject to parental/guardian consent
Exclusion criteria
There is no exclsion criteria
Time frame: 6 weeks turnaround for each sample
The image and analysis by the application are performed within 10 minutes of the patient giving consent to be part of this study. The biopsy that will be used for comarison with the image analysis will be available to the Investigators approximatly 6 weeks later
Moletest Scotland Ltd
Industry
A Clinical Study to Evaluate the Ability of an iPad Based Photographic Image Analysis System to Discriminate Benign Skin Lesions From Those Considered Suspect for Melanoma
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02718066
Adenocarcinoma, Bronchial Neoplasms
Phoenix, Arizona, United States
View Trial DetailsNCT00429312
Melanoma, Neoplasms
Los Angeles, California, United States
View Trial DetailsNCT06666634
Genital Diseases, Genital Diseases, Male
Amsterdam, Netherlands
View Trial DetailsNCT02724488
Head and Neck Cancer, Head and Neck Neoplasms
View Trial Details